A dissemination and education programme to improve the clinical behaviours of psychiatrists in accordance with treatment guidelines for schizophrenia and major depressive disorders: the Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE) project.
Clinical practice guidelines
EGUIDE project
educational programme
major depressive disorder
schizophrenia
Journal
BJPsych open
ISSN: 2056-4724
Titre abrégé: BJPsych Open
Pays: England
ID NLM: 101667931
Informations de publication
Date de publication:
21 Apr 2022
21 Apr 2022
Historique:
entrez:
21
4
2022
pubmed:
22
4
2022
medline:
22
4
2022
Statut:
epublish
Résumé
Clinical practice guidelines for schizophrenia and major depressive disorder have been published. However, these have not had sufficient penetration in clinical settings. We developed the Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE) project as a dissemination and education programme for psychiatrists. The aim of this study is to assess the effectiveness of the EGUIDE project on the subjective clinical behaviour of psychiatrists in accordance with clinical practice guidelines before and 1 and 2 years after participation in the programmes. A total of 607 psychiatrists participated in this study during October 2016 and March 2019. They attended both 1-day educational programmes based on the clinical practice guidelines for schizophrenia and major depressive disorder, and answered web questionnaires about their clinical behaviours before and 1 and 2 years after attending the programmes. We evaluated the changes in clinical behaviours in accordance with the clinical practice guidelines between before and 2 years after the programme. All of the scores for clinical behaviours in accordance with clinical practice guidelines were significantly improved after 1 and 2 years compared with before attending the programmes. There were no significant changes in any of the scores between 1 and 2 years after attending. All clinical behaviours in accordance with clinical practice guidelines improved after attending the EGUIDE programme, and were maintained for at least 2 years. The EGUIDE project could contribute to improved guideline-based clinical behaviour among psychiatrists.
Sections du résumé
BACKGROUND
BACKGROUND
Clinical practice guidelines for schizophrenia and major depressive disorder have been published. However, these have not had sufficient penetration in clinical settings. We developed the Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE) project as a dissemination and education programme for psychiatrists.
AIMS
OBJECTIVE
The aim of this study is to assess the effectiveness of the EGUIDE project on the subjective clinical behaviour of psychiatrists in accordance with clinical practice guidelines before and 1 and 2 years after participation in the programmes.
METHOD
METHODS
A total of 607 psychiatrists participated in this study during October 2016 and March 2019. They attended both 1-day educational programmes based on the clinical practice guidelines for schizophrenia and major depressive disorder, and answered web questionnaires about their clinical behaviours before and 1 and 2 years after attending the programmes. We evaluated the changes in clinical behaviours in accordance with the clinical practice guidelines between before and 2 years after the programme.
RESULTS
RESULTS
All of the scores for clinical behaviours in accordance with clinical practice guidelines were significantly improved after 1 and 2 years compared with before attending the programmes. There were no significant changes in any of the scores between 1 and 2 years after attending.
CONCLUSIONS
CONCLUSIONS
All clinical behaviours in accordance with clinical practice guidelines improved after attending the EGUIDE programme, and were maintained for at least 2 years. The EGUIDE project could contribute to improved guideline-based clinical behaviour among psychiatrists.
Identifiants
pubmed: 35446248
doi: 10.1192/bjo.2022.44
pii: S2056472422000448
pmc: PMC9059732
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e83Subventions
Organisme : the Health and Labor Sciences Research Grants the Japanese Society of Neuropsychopharmacology the Japanese Society of Mood Disorders Japan Agency for Medical Research and Development Japan Agency for Medical Research and Development Japan Agency for Medical Research and Development
Références
Neuropsychopharmacol Rep. 2021 Sep;41(3):266-324
pubmed: 34390232
Psychiatry Clin Neurosci. 2019 Oct;73(10):642-648
pubmed: 31437336
Eur Psychiatry. 2015 Mar;30(3):388-404
pubmed: 25749390
Schizophr Res. 2012 Jun;138(1):18-28
pubmed: 22534420
BMC Psychiatry. 2013 May 27;13:150
pubmed: 23705908
J Clin Psychopharmacol. 2018 Dec;38(6):598-603
pubmed: 30273199
Psychiatry Clin Neurosci. 2018 Aug;72(8):572-579
pubmed: 29761577
Int J Psychiatry Clin Pract. 2017 Jun;21(2):82-90
pubmed: 28498090
Neuropsychopharmacol Rep. 2020 Sep;40(3):281-286
pubmed: 32602667
Psychiatry Clin Neurosci. 2020 Jun;74(6):344-353
pubmed: 32048773
Implement Sci. 2020 Jul 1;15(1):50
pubmed: 32611354
Eur Arch Psychiatry Clin Neurosci. 2017 Dec;267(8):711-721
pubmed: 28421334
Psychiatry Clin Neurosci. 2015 Sep;69(9):553-62
pubmed: 25601043
Can J Psychiatry. 2016 Sep;61(9):540-60
pubmed: 27486148
BMJ. 2014 Feb 12;348:g1173
pubmed: 24523363
Psychiatry Clin Neurosci. 2009 Apr;63(2):244-6
pubmed: 19175759
Cochrane Database Syst Rev. 2016 Dec 15;12:CD009780
pubmed: 27977851
JAMA. 1999 Oct 20;282(15):1458-65
pubmed: 10535437
Brain Nerve. 2012 Oct;64(10):1159-65
pubmed: 23037606
BMJ Open. 2017 Jan 6;7(1):e013881
pubmed: 28062471
Neuropsychopharmacol Rep. 2021 Jun;41(2):199-206
pubmed: 33704931
Int J Psychiatry Clin Pract. 2017 Sep;21(3):166-176
pubmed: 28367707
Asian J Psychiatr. 2021 Sep;63:102744
pubmed: 34325252
Psychiatry Clin Neurosci. 2020 Dec;74(12):667-669
pubmed: 32881226
Can J Psychiatry. 2017 Sep;62(9):604-616
pubmed: 28703015
Br J Psychiatry. 2005 Sep;187:243-7
pubmed: 16135861